Windlas Biotech hosting analyst meet on 14 Jul 2026

0 min read     Updated on 12 Jul 2026, 09:24 PM
scanx
Reviewed by
Ashish TScanX News Team
AI Summary

Windlas Biotech has scheduled a virtual meeting for analysts and institutional investors on July 14, 2026, at 3:00 PM IST under SEBI regulations. The company stated that discussions will rely on publicly available documents and no unpublished price sensitive information will be disclosed.

powered bylight_fuzz_icon
45158353

*this image is generated using AI for illustrative purposes only.

Windlas Biotech has scheduled a virtual meeting for analysts and institutional investors on July 14, 2026. The session is set to commence at 3:00 PM IST and will be conducted in a group format. This initiative is part of the company's engagement efforts under the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

The company confirmed that the discussions during the meeting will be based solely on publicly available documents. It explicitly stated that no unpublished price sensitive information (UPSI) will be shared during the session. Windlas Biotech noted that the schedule is subject to change due to exigencies on the part of investors, analysts, or the company.

Meeting Details

Date Type Mode Time
Tuesday, July 14, 2026 Group Meeting Virtual 3:00 PM onwards

The intimation was submitted to the stock exchanges pursuant to Regulation 30(6) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Ananta Narayan Panda, Company Secretary & Compliance Officer, signed the filing on July 9, 2026.

Historical Stock Returns for Windlas Biotech

1 Day5 Days1 Month6 Months1 Year5 Years
+0.49%-3.63%-0.65%+10.42%-10.55%+103.84%

What strategic updates or growth initiatives is Windlas Biotech likely to emphasize during the meeting?

How might the market react to the company's engagement efforts under SEBI regulations?

Could this meeting signal upcoming corporate actions or partnerships for Windlas Biotech?

Windlas Biotech fixes July 16 record date for ₹6.30 dividend

1 min read     Updated on 02 Jul 2026, 04:05 PM
scanx
Reviewed by
Riya DScanX News Team
AI Summary

Windlas Biotech has fixed July 16, 2026, as the record date to determine eligibility for a final dividend of ₹6.30 per equity share for FY26. The 25th AGM is scheduled for July 23, 2026, via video conferencing, with remote e-voting available from July 20 to July 22. The agenda includes financial statement adoption, dividend declaration, and director re-appointments.

powered bylight_fuzz_icon
44354075

*this image is generated using AI for illustrative purposes only.

Windlas Biotech Limited has fixed Thursday, July 16, 2026, as the record date to determine members eligible for a final dividend of ₹6.30 per equity share for the financial year ended March 31, 2026. The dividend, recommended at 126% of the face value of ₹5 each, is subject to shareholder approval at the upcoming 25th Annual General Meeting (AGM) scheduled for July 23, 2026. The payment will be made within 30 days from the date of declaration at the AGM, subject to tax deduction at source.

AGM and E-Voting Details

The 25th AGM will be held on Thursday, July 23, 2026, at 1:00 P.M. via Video Conferencing (VC) and Other Audio Visual Means (OAVM), in compliance with Ministry of Corporate Affairs (MCA) Circular No. 20/2020 and General Circular No. 03/2025. Members attending through VC will be counted for quorum purposes under Section 103 of the Companies Act, 2013. Remote e-voting will be available from July 20, 2026 (9:00 A.M.) to July 22, 2026 (5:00 P.M.), facilitated by MUFG Intime India Private Limited.

Agenda for the Meeting

Key agenda items include the adoption of audited standalone and consolidated financial statements for FY26, the declaration of the final dividend, and the re-appointment of Mr. Hitesh Windlass and Mrs. Prachi Jain Windlass as directors liable to retire by rotation. Additionally, the meeting will seek ratification for the remuneration of the Cost Auditor, M/s Sourabh Jain & Associates, at ₹60,000 excluding GST for FY27. Shareholders will also vote on the appointment of Dr. Tarashree Singhal as an Independent Woman Director for a five-year term from May 5, 2026, to May 4, 2031.

Director Re-appointments

Mr. Hitesh Windlass (DIN: 02030941), Managing Director, and Mrs. Prachi Jain Windlass (DIN: 06661073), Non-Executive Director, are eligible for re-appointment. Mr. Hitesh Windlass has been with the company since January 21, 2008, and holds a bachelor's degree in ceramic engineering from IIT Banaras Hindu University and an MBA from the University of Chicago. Mrs. Prachi Jain Windlass, appointed on May 3, 2021, holds a bachelor's degree in technology from IIT Delhi and master's degrees from the University of Southern California and the University of Chicago.

Historical Stock Returns for Windlas Biotech

1 Day5 Days1 Month6 Months1 Year5 Years
+0.49%-3.63%-0.65%+10.42%-10.55%+103.84%

What is the expected impact of the dividend payout on Windlas Biotech's cash flow and capital allocation plans for FY27?

How will the re-appointment of key directors influence the company's strategic direction and growth initiatives over the next term?

What are the potential market reactions to the appointment of Dr. Tarashree Singhal as an Independent Woman Director?

More News on Windlas Biotech

Must Read Next

Earnings

Corporate Actions

Stocks

1 Year Returns:-10.55%